Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT05216822 |
| Other study ID # |
IRB-2/2019AZA |
| Secondary ID |
|
| Status |
Completed |
| Phase |
Phase 1
|
| First received |
|
| Last updated |
|
| Start date |
June 1, 2018 |
| Est. completion date |
August 31, 2018 |
Study information
| Verified date |
January 2022 |
| Source |
Assiut University |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
In conclusion, racecadotril is an anti-secretory drug that exerts its antidiarrheal effect by
inhibiting intestinal enkephalinase. It is effective in reducing the volume and frequency of
stool output. racecadotril is well tolerated and safe by providing symptomatic relief and
reducing the severity of diarrhea as an adjuvant therapy during the acute attack of
gastroenteritis. It is recommended that the new generations of already discovered drugs for
control of secretory diarrhea should be studied to discover the ones with fewer side effects
to other systems in the body.
Description:
Background: Previous studies have shown that racecadotril is a safe and effective drug in
treating children with acute diarrhea. Study Aim: to evaluate the effect of racecadotril as
an adjunct to oral rehydration solution in the treatment of acute watery diarrhea among
children under 5 years of age. Subjects and methods: This RCT trial included 50 children with
acute watery diarrhea for 5 days or less with a frequency of three or more diarrheic stools
in the past 24 hours before admission to the hospital, with no/mild to moderate dehydration.
